Achievement of Medium-Term Strategy "Stage 4"
First written in FY2023. 3 of 6 entries say "Advanced", first in FY2025. Latest entry: 2026-06-30.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「During the interim consolidated accounting period, the company changed its reportable segments to reorganize its portfolio in line with its business strategy. This followed the positioning of the life sciences AI business as a core business toward achieving the medium-term management plan (Stage 4) for the fiscal year ending March 2029, and the decision to strengthen its DX business for the manufacturing industry by making Alnetz Co., Ltd. a subsidiary on 30 April 2025.」
To achieve Stage 4 in the fiscal year ending March 2029, the company reorganized its portfolio around life sciences AI as a core business and incorporated the strengthening of its DX business for the manufacturing industry through the acquisition of Alnetz as a subsidiary. - FY2025AdvancedAnnual report
「To achieve the medium-term management plan (Stage 4) for the fiscal year ending March 2029, we will position the life sciences AI field as our core business and continue making proactive upfront investments.」
The company continued its plan to make the fiscal year ending March 2029 the final year of Stage 4 and clarified its investment policy centered on life sciences AI. Co-creation projects reached 7 contracts against a KPI of 3. - FY2024SoftenedAnnual report
「We aim to achieve medium-term strategy "Stage 4" in the fiscal year ending March 2029.」
The target timing for achievement of medium-term strategy "Stage 4" changed from the fiscal year ending March 2028, as indicated in FY2023, to the fiscal year ending March 2029. - FY2023First statedAnnual report
「We are currently making every effort as a group to achieve our medium-term strategy, "Stage 4," which we aim to achieve in the 25th fiscal year, the fiscal year ending March 2028.」
The company presented its medium-term strategy, "Stage 4," with the fiscal year ending March 2028 as its target for achievement, for the first time in a comprehensive format, and positioned the fiscal year ending March 2024 as the year for establishing the AI drug discovery and economic security business models and building the foundation for recovery.